News Quantified

Stock Stats

News Stats


All News	{{AllNewsCount}}
News Wires	{{NewsWiresCount}}
Media Monitoring	{{MoreOverCount}}
SEC Edgar Filings	{{SecEdgarFilingsCount}}
Upgrades	{{UpgradesCount}}
Downgrades	{{DowngradesCount}}
Initiated	{{InitiatesCount}}
Reiterated	{{ReiteratesCount}}
Last Earnings	{{LastEarnings}}
Last Earnings EPS	{{LastEps}}
Next Earnings	{{NextEarnings}}

Order Stats

Sub-Penny
{{SubPennyStr}}
Odd Lot
{{OddLotStr}}
Avg. bid-ask spread

{{GetAvgBidAskSpreadForScale}}
Avg. bid / ask size
{{GetAvgBidSizeForScale}} {{GetAvgAskSizeForScale}}

Shares at ask / bid
{{SharesAtAsk_AMP_Str}} {{SharesAtBid_AMP_Str}}
Off exchange
{{OffExchange}}

News

Axogen Inc. Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration (FDA) for Avance Nerve Graft® [Yahoo! Finance]

Axogen Inc. Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration (FDA) for Avance Nerve Graft®

Axogen, Inc to Participate at Leerink Partners Healthcare Crossroads Conference [Yahoo! Finance]

Axogen, Inc to Participate at Leerink Partners Healthcare Crossroads Conference

AxoGen, Inc. (NASDAQ: AXGN) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.

5/2/2024

07:00 am

axgn

-8.1%

BEAT

3/5/2024

07:00 am

axgn

-15.2%

BEAT

11/7/2023

07:00 am

axgn

40.0%

BEAT

8/7/2023

04:01 pm

axgn

-19.4%

BEAT

Form 10-Q Axogen, Inc. For: Mar 31

Form 8-K Axogen, Inc. For: May 02

Form EFFECT Axogen, Inc.

Form DEF 14A Axogen, Inc. For: Jun 05

Form ARS Axogen, Inc. For: Dec 31

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}